A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study.
Hui-Jen Tsai, Skye Hung-Chun Cheng, Shih-Neng Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicentre randomized controlled trial tested whether epigallocatechin gallate (EGCG) reduces Epstein-Barr virus (EBV) reactivation in patients with nasopharyngeal carcinoma (NPC) in remission after radiation-based treatment. Participants with complete response and negative plasma EBV DNA were assigned to EGCG or placebo for 3 years; 327 patients were evaluable. EGCG was minimally toxic and well tolerated, but the trial found no significant difference between groups in EBV DNA reactivation or tumor recurrence. Positive plasma EBV DNA was associated with higher recurrence and shorter recurrence-free and overall survival.
Key findings
- Of 353 included patients, 327 were evaluable; 161 received EGCG and 166 received placebo.
- EGCG was minimally toxic and well tolerated.
- There was no significant difference in EBV DNA reactivation or recurrence between the EGCG and placebo groups.
- Positive plasma EBV DNA was associated with higher recurrence and shorter recurrence-free and overall survival.
Why it matters
The trial does not support EGCG as a means of preventing EBV reactivation or tumor recurrence in NPC remission. In contrast, the association between detectable plasma EBV DNA and poorer clinical outcomes supports its potential value as a surveillance marker, while not establishing that monitoring itself improves outcomes.
What to keep in mind
The abstract does not report effect estimates for the between-group comparisons, limiting assessment of the magnitude of any difference.